1. Home
  2. HYPR vs ICCC Comparison

HYPR vs ICCC Comparison

Compare HYPR & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyperfine Inc.

HYPR

Hyperfine Inc.

HOLD

Current Price

$0.95

Market Cap

104.0M

Sector

Health Care

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$6.04

Market Cap

55.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HYPR
ICCC
Founded
2014
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
104.0M
55.5M
IPO Year
N/A
1987

Fundamental Metrics

Financial Performance
Metric
HYPR
ICCC
Price
$0.95
$6.04
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$1.28
N/A
AVG Volume (30 Days)
594.5K
22.4K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.26
Revenue
$10,591,000.00
$27,769,304.00
Revenue This Year
$5.17
N/A
Revenue Next Year
$35.44
N/A
P/E Ratio
N/A
$24.05
Revenue Growth
N/A
16.49
52 Week Low
$0.53
$4.28
52 Week High
$2.22
$7.60

Technical Indicators

Market Signals
Indicator
HYPR
ICCC
Relative Strength Index (RSI) 41.70 59.47
Support Level $0.85 $4.72
Resistance Level $1.08 $5.36
Average True Range (ATR) 0.08 0.35
MACD 0.00 0.16
Stochastic Oscillator 41.60 87.01

Price Performance

Historical Comparison
HYPR
ICCC

About HYPR Hyperfine Inc.

Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

Share on Social Networks: